LAI Recommendations for the Use of Bempedoic Acid
- Studies show 15% to 25% LDL-C reduction on background statin therapy; higher LDL-C reduction in patients not on statins.
- Combination of bempedoic acid and ezetimibe lowers LDL-C by about 35% to 40%.
- Bempedoic acid not activated in muscle.
- Overall good safety profile: uric acid increase, small increased incidence of tendon rupture. Pending CV outcomes study.
Dr. P Barton Duell
Dr. P Barton Duell is a Professor of Medicine, Division of Cardiovascular Medicine, School of Medicine. He currently serves as the director of OHSU's Metabolic Disorders Clinic. He received his medical degree from OHSU in 1983, and completed his medicine residency at OHSU and the University of Chicago. He completed his metabolism, endocrinology and nutrition fellowship at the University of Washington in Seattle.
More FAQs by Dr. P Barton Duell
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please login to comment on this article